New drug AIR-001 enters first human tests for rare lung disease
NCT ID NCT07431112
First seen Feb 27, 2026 · Last updated May 21, 2026 · Updated 12 times
Summary
This early-stage study tests a new drug called AIR-001 in 54 adults with alpha-1 antitrypsin deficiency (AATD) who have a specific genetic type (PiZZ). The main goal is to check the drug's safety and how the body processes it. Participants receive one or more doses under the skin, and researchers monitor side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Study Center
RECRUITINGMelbourne, Australia
-
Clinical Study Center
RECRUITINGLondon, United Kingdom
-
Clinical Study Center 1
RECRUITINGTbilisi, Georgia
-
Clinical Study Center 2
RECRUITINGTbilisi, Georgia
Conditions
Explore the condition pages connected to this study.